Full-Time

Director - Business Development

Mid-Atlantic Region / Southeast

Posted on 11/30/2025

Deadline 3/30/26
PCI Pharma Services

PCI Pharma Services

1-10 employees

Pharmaceutical packaging and contract services

No salary listed

Philadelphia, PA, USA

Remote

Category
Business & Strategy (1)
Required Skills
Sales
Requirements
  • Bachelor’s degree in Life Sciences, Biotechnology, Chemistry, or related discipline.
  • 10+ years of progressive sales or business development experience in the CDMO or pharmaceutical services industry.
  • Proven track record of closing complex, multi-million-dollar programs and long-cycle sales.
  • In-depth knowledge of drug development and manufacturing processes, particularly for sterile products.
  • Scientific fluency and credibility when engaging with technical and executive stakeholders.
  • Ability to travel frequently (up to 40–50%) to client sites, PCI facilities, and industry events.
Responsibilities
  • Develop and execute a territory growth strategy, integrating sales planning, pipeline development, and competitive intelligence to meet quarterly and annual revenue targets.
  • Build strategic, consultative relationships with C-level stakeholders, decision-makers, and influencers within target biotech and pharmaceutical accounts.
  • Actively manage a balanced portfolio of new business development (80%) and account management (20%).
  • Lead complex, multi-stakeholder negotiations for MSAs, CDAs, pricing proposals, and service agreements, collaborating with legal, finance, and technical functions.
  • Work cross-functionally with PCI’s global proposal, technical, quality, and operational teams to shape scientifically credible, client-aligned solutions.
  • Ensure accurate demand forecasting to inform S&OP processes, capacity planning, and financial projections.
  • Drive internal alignment through Salesforce updates, forecasting inputs, and regular communication with executive and cross-functional teams.
  • Provide strategic feedback and insights to marketing, product management, and service development teams to enhance PCI’s market responsiveness and brand presence.
  • Work closely with cross segment teams to drive end to end service opportunities through attending tradeshows, hosting local events, joint lunch and learns and building a targeted plan to cross promote.
  • Identify emerging client needs in early-phase development, novel modalities, and in-home/integrated care models.
  • Partner with marketing to develop regionally tailored campaigns, thought leadership content, and participation in key industry events.
Desired Qualifications
  • Advanced degree preferred.
  • CRM proficiency (e.g., Salesforce) and experience with forecasting tools and sales analytics.
  • Deep understanding of pharma/biotech market dynamics, commercialization models, and client decision-making processes.

PCI Pharma Services offers end-to-end pharmaceutical packaging and related services, including Folding Cartons, Labels, Contract Packaging, Clinical Services, and Brand Protection. It serves as a one-stop source for healthcare product developers and manufacturers, handling carton and label production, packaging operations, clinical services, and brand protection under one roof. The company stands out with eight decades of experience, strict cGMP and ISO compliance, lean manufacturing, ongoing R&D, and comprehensive employee training, security, hygiene, and inspection practices. Its goal is to be a trusted, end-to-end packaging partner that delivers reliable, compliant, and scalable packaging solutions, so clients can focus on their core business.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$4B

Headquarters

Burlington, Canada

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • GLP-1 surge drives demand for PCI's prefilled syringes and autoinjectors.
  • Oncology-CNS pipelines favor PCI's patient-centric drug-device combinations.
  • Bain Capital's $10B valuation fuels $1B capacity expansions through 2028.

What critics are saying

  • San Diego isolator line delays to H1 2028 cede contracts to Lonza.
  • Novo Nordisk's Catalent acquisition slashes external CDMO fill-finish availability.
  • PE backers force divestitures if biotech funding dries post-2025.

What makes PCI Pharma Services unique

  • PCI integrates sterile fill-finish with drug-device assembly for end-to-end injectables.
  • Ajinomoto Althea acquisition adds rare US high-potent ADC sterile filling expertise.
  • AVI systems inspect 75 million vials annually, scaling quality without bottlenecks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Company News

BioProcess International
Aug 15th, 2025
Building a better facility: BPI tours PCI manufacturing plant in Bedford

On the last day of June 2025's BIO conference in Boston, Massachusetts, contract development and manufacturing organization (CDMO) PCI Pharma Services bused a crowd of delegates to its manufacturing site in Bedford, New Hampshire where it hosted a tour of its 50,000 square-foot expansion.

Montgomery County
Jul 24th, 2025
PCI Pharma Services Valued at $10B

PCI Pharma Services in Northeast Philadelphia has received a multibillion-dollar investment from Bain Capital and Kohlberg, valuing the company at $10 billion. Kohlberg had previously invested in PCI, while Bain is a new investor. The investment will help PCI expand its services and geographic reach. The company currently operates 38 sites across seven countries and employs over 7,500 people.

JD Supra
Jul 16th, 2025
Healthcare & Life Sciences Private Equity Deal Tracker: Bain Capital and Kohlberg Invest in PCI Pharma

Healthcare & life sciences Private Equity deal tracker: Bain Capital and Kohlberg invest in PCI Pharma.

FinSMEs
Jul 15th, 2025
PCI Pharma Services Receives Investment from Mubadala, Bain Capital, and Kohlberg

PCI Pharma, a Philadelphia, PA-based contract development and manufacturing organization (CDMO) focused on biotherapies, received an investment from Bain Capital, Kohlberg, and Mubadala Investment Company.

MarketScreener
Jul 14th, 2025
PCI Pharma Services receives new funding

PCI Pharma Services announced it received a new round of funding on July 14, 2025. The funding was co-led by new investor Bain Capital, LP, and returning investor Kohlberg & Company, L.L.C. Additional participation came from returning investors Mubadala Investment Company PJSC and Partners Group Holding AG.

INACTIVE